<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798715</url>
  </required_header>
  <id_info>
    <org_study_id>GRC/1/21/1044</org_study_id>
    <nct_id>NCT05798715</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp &amp; Dohme, The Netherlands)</brief_title>
  <official_title>Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to Determine the Bioequivalence of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma for Pharmaceuticals &amp; Medical Appliances, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp &amp; Dohme, The Netherlands) After a Single Oral Dose Administration of Each to Healthy Adults Under Fed Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genuine Research Center, Egypt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eva Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genuine Research Center, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to determine the&#xD;
      bioequivalence of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and&#xD;
      Janumet 50/1000 mg F.C.Tablets (Merck Sharp &amp; Dohme, The Netherlands)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers, 18-55 years of age, selected from the Egyptian population fulfilling the&#xD;
      selection criteria. All dosed subject samples will be analyzed and their data will be&#xD;
      included in the final study report.&#xD;
&#xD;
      Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic&#xD;
      Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the&#xD;
      90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for&#xD;
      untransformed data of Ke, tmax and t1/2e.&#xD;
&#xD;
      The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax,&#xD;
      AUC0→t and AUC0→∞ to be within 80.00-125.00%.&#xD;
&#xD;
      A comprehensive final report will be issued upon the completion of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2022</start_date>
  <completion_date type="Actual">January 13, 2023</completion_date>
  <primary_completion_date type="Actual">December 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 36 hours post dose in each treatment period</time_frame>
    <description>to measure the maximal measured plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 36 hours post dose in each treatment period</time_frame>
    <description>time of the maximum plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet contains 1000 mg Metformin HCl &amp; 50 mg Sitagliptin orally administrated with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet contains 1000 mg Metformin HCl &amp; 50 mg Sitagliptin orally administrated with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleptomet 50/1000(Metformin HCl &amp; Sitagliptin)</intervention_name>
    <description>Test drug</description>
    <arm_group_label>T test</arm_group_label>
    <other_name>Janumet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Janumet 50/1000(Metformin HCl &amp; Sitagliptin)</intervention_name>
    <description>Reference drug</description>
    <arm_group_label>R Reference</arm_group_label>
    <other_name>Janumet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female, age 18 to 55 years, inclusive.&#xD;
&#xD;
          2. Body weight within 15% of normal range (18.5-30.0) according to the accepted normal&#xD;
             values for body mass index (BMI).&#xD;
&#xD;
          3. Medical demographics without evidence of clinically significant deviation from normal&#xD;
             medical condition, eg.: no history of heart, liver, kidney, gastrointestinal, nervous&#xD;
             system, or metabolic abnormalities.&#xD;
&#xD;
          4. Results of clinical laboratory test are within the normal range or with a deviation&#xD;
             that is not considered clinically significant by principal investigator.&#xD;
&#xD;
          5. Females should be on a suitable birth control method.&#xD;
&#xD;
          6. Fully informed subjects that consented to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with known allergy to the products tested.&#xD;
&#xD;
          2. Subjects who meet any of the contraindications to the administration of Sitagliptin&#xD;
             and/or Metformin HCl.&#xD;
&#xD;
          3. Subjects who are going to get an injection of dye or contrast agents for an x-ray&#xD;
             procedure.&#xD;
&#xD;
          4. Subject does not agree not to consume any medication or food which may affect CYP3A4&#xD;
             enzyme at least one week prior to first study drug administration until donating the&#xD;
             last sample of the study.&#xD;
&#xD;
          5. Subjects that do not agree not to consume alcohol-containing beverages and foods for 1&#xD;
             week before dosing and throughout the period of sample collection.&#xD;
&#xD;
          6. Heavy smokers.&#xD;
&#xD;
          7. Female subjects who were pregnant or nursing.&#xD;
&#xD;
          8. Acute infection within one week preceding first study drug administration.&#xD;
&#xD;
          9. History of drug or alcohol abuse.&#xD;
&#xD;
         10. Subject does not comply with the stated instruction of not taking any prescription or&#xD;
             non-prescription drugs within two weeks before first study drug administration and&#xD;
             until the end of the study.&#xD;
&#xD;
         11. Subject is on a special diet (for example subject is vegetarian).&#xD;
&#xD;
         12. Subject does not agree not to consume any beverages or foods containing&#xD;
             methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to&#xD;
             the study administration of either study period until donating the last sample in each&#xD;
             respective period.&#xD;
&#xD;
         13. Subject does not agree not to consume any beverages or foods containing grapefruit 7&#xD;
             days prior to first study drug administration until the end of the study.&#xD;
&#xD;
         14. Subject has a family history of severe diseases which have direct impact on the study.&#xD;
&#xD;
         15. Participation in a bioequivalence study or in a clinical study within the last 60&#xD;
             days, before first study drug administration.&#xD;
&#xD;
         16. Subject intends to be hospitalized within 3 months after first study drug&#xD;
             administration.&#xD;
&#xD;
         17. Subjects who have blood donated or lost more than 500 mL blood within 3 months prior&#xD;
             to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elshafeey, Ph.D. Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Genuine Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genuine Research Center GRC</name>
      <address>
        <city>Cairo</city>
        <zip>11757</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/ema</url>
    <description>Description: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) The European Agency for the Evaluation of Medicinal Products (EMEA) May 1997</description>
  </link>
  <link>
    <url>http://www.ema.europa.eu/ema</url>
    <description>Note for Guidance on Clinical Safety Data Management; Definitions And Standards for Expedited Reporting (CPMP/ICH/377/95) The European Agency for the Evaluation of Medicinal Products (EMEA) June 1995.</description>
  </link>
  <reference>
    <citation>Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. doi: 10.1023/a:1011503032353. Erratum In: J Pharmacokinet Pharmacodyn. 2002 Feb;29(1):101.</citation>
    <PMID>11381568</PMID>
  </reference>
  <reference>
    <citation>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419.</citation>
    <PMID>3450848</PMID>
  </reference>
  <reference>
    <citation>Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.</citation>
    <PMID>2004861</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

